STOCK TITAN

Moderna Inc - MRNA STOCK NEWS

Welcome to our dedicated news page for Moderna (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Moderna's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Moderna's position in the market.

News
Rhea-AI Summary
CARsgen Therapeutics Holdings (2171.HK) announced its 2023 Annual Results, highlighting NDA and IND approvals, successful clinical trials, collaboration agreements with Huadong Medicine and Moderna, and advancements in CAR T-cell therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
none
-
Rhea-AI Summary
Blackstone Life Sciences partners with Moderna to invest $750 million in mRNA technology for influenza program, aiming to advance vaccine development and impact human health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
none
-
Rhea-AI Summary
Blackstone Life Sciences partners with Moderna to invest $750 million in mRNA technology for influenza program, aiming to advance vaccine development and impact human health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
none
Rhea-AI Summary
Moderna, Inc. announces successful Phase 3 endpoints for its fourth respiratory vaccine candidate, with positive clinical trial data from three new vaccines against significant viruses. The company expects two more Phase 3 readouts in 2024, including a combination flu and COVID-19 vaccine. Moderna also secures funding of up to $750 million for flu program and anticipates the U.S. launch of an RSV vaccine in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
clinical trial
-
Rhea-AI Summary
Moderna's mRNA-1283 COVID-19 vaccine shows a higher immune response than mRNA-1273.222, paving the way for a combination vaccine against influenza and COVID-19. The Phase 3 trial demonstrated efficacy across different virus strains and age groups, with positive safety profiles and potential storage advantages.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.69%
Tags
clinical trial covid-19
-
Rhea-AI Summary
Moderna, Inc. (MRNA) will host its fifth annual Investor Event on March 27, 2024, focusing on vaccines and business updates. The event will feature presentations on Moderna's pipeline of mRNA vaccines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.38%
Tags
conferences
Rhea-AI Summary
Moderna, Inc. (MRNA) is set to participate in upcoming investor conferences including TD Cowen 44th Annual Healthcare Conference and Barclays 26th Annual Global Healthcare Conference. The presentations will be live webcasted and available for replay on Moderna's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
conferences
-
Rhea-AI Summary
Moderna, Inc. (MRNA) reported fourth quarter revenues of $2.8 billion, with a net income of $217 million and diluted EPS of $0.55. Full-year revenues were $6.8 billion, with a net loss of $(4.7) billion and diluted EPS of $(12.33). The company reaffirmed 2024 expected product sales of $4 billion and expects regulatory approvals for its investigational RSV vaccine in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.53%
Tags
earnings
-
Rhea-AI Summary
Moderna, Inc. announced that CEO Stéphane Bancel has been elected to the National Academy of Engineering for his contributions to engineering and the development and manufacturing of pharmaceutical products, including the COVID-19 vaccine. Bancel has been with Moderna for 13 years, leading the company from startup to global commercial enterprise. The company has 45 mRNA therapeutic and vaccine programs in its pipeline, with nine in late-stage development. Bancel's previous experience includes roles at bioMérieux SA and Eli Lilly and Company. Moderna's co-founder and Chairman, Noubar Afeyan, was also elected to the Academy in 2022. The NAE's mission is to advance the welfare and prosperity of the nation by providing independent advice on matters involving engineering and technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
none
Rhea-AI Summary
Moderna, Inc. (MRNA) will host a live conference call and webcast to report its fourth quarter and full year 2023 financial results and provide a corporate update on February 22, 2024. The webcast will be available on the Moderna website under 'Events and Presentations' and will be archived for one year after the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
conferences earnings
Moderna Inc

Nasdaq:MRNA

MRNA Rankings

MRNA Stock Data

42.34B
344.83M
9.63%
71.82%
5.79%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Cambridge

About MRNA

moderna is pioneering messenger rna therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. this breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions. moderna has developed a broad intellectual property estate including more than 200 patent applications with more than 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions. the company plans to develop and commercialize its innovative mrna drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutics areas in order to rapidly deliver this innovation to patients. based in cambridge, massachusetts, moderna is privately held and was founded in 2010 by flagship venturelabs in association with leading scientists from boston children’s hospital a